Not all biomarkers should be used as surrogate endpoints to assess clinical outcomes.  Biomarkers can be difficult to validate and require different levels of validation depending on their intended use.  If a biomarker is to be used to measure the success of a therapeutic intervention, the biomarker should reflect a direct effect of that medicine.